Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Conference attendees have access to Convergence on-demand content until 31 January 2022.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
Hone in on the sector knowledge you need with RAPS' Fundamentals of Pharmaceutical and Biologics Regulations and Fundamentals of Medical Device Regulations.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 09 February 2012 | By Alexander Gaffney, RAC
A coalition led by the Center for Reproductive Rights (CRR) on 8 February sought to overturn a decision made by US Department of Health and Human Services (DHHS) Secretary Kathleen Sebelius. The group appeared before Judge Edward Korman of the US District Court in Brooklyn, NY, to petition the court to re-open a lawsuit that would allow those under the age of 17 to access the "morning-after-pill" levonorgestrel without a doctor's prescription.
While the US Food and Drug Administration (FDA) approved the use of levonorgestrel for those under the age of 17 in late 2011, Sebelius overturned FDA's decision before it could be implemented because she believed there was insufficient evidence to support the sponsor's claims.
Retuers notes the reversal was "the first time in agency history the [D]HHS overruled a scientific recommendation from FDA."
The coalition also asked Korman to add Sebelius as a defendant to the lawsuit, saying that "the path towards OTC status for post-coital contraception has been unnecessarily complicated by political interference."
Tags: Morning After Pill, Levonorgestrel, CRR, Lawsuit, Plan B, Sebelius, Latest News, DHHS
Regulatory Focus newsletters
All the biggest regulatory news and happenings.